We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atherosclerotic Plaque Characterization (APC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00861653
First Posted: March 13, 2009
Last Update Posted: April 15, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Piedmont Healthcare
March 11, 2009
March 13, 2009
April 15, 2014
October 2006
August 2011   (Final data collection date for primary outcome measure)
Characterization of plaque that is found in the carotid walls of patients who have atherosclerosis [ Time Frame: 2 years post study initiation ]
Characterization of plaque that is found in the carotid walls of patients who have atherosclerosis [ Time Frame: 1 Year ]
Complete list of historical versions of study NCT00861653 on ClinicalTrials.gov Archive Site
To evaluate the effectiveness of MR imaging in identifying these plaque characteristics [ Time Frame: 2 Years Post Study Initiation ]
To evaluate the effectiveness of MR imaging in identifying these plaque characteristics [ Time Frame: 1 Year ]
Not Provided
Not Provided
 
Atherosclerotic Plaque Characterization
Atherosclerotic Plaque Characterization Using Multispectral, Multicontrast High Resolution Cardiovascular Magnetic Resonance Imaging
The purpose of this study is to utilize high-resolution CMR carotid imaging for the characterization of carotid wall volumes and plaque content in patients with clinical significant carotid atherosclerosis. Patients who are scheduled to undergo an imaging procedure will be recruited from the cath lab. Upon enrollment, blood samples conventional and genetic profiling will be collected. For patients undergoing a carotid endarterectomy, tissue from the carotid vessel will be collected during their procedure. Comparison of the MR images with tissue and/or blood samples will be made. Length of time in the study will be approximately 1 day. There will be no study-related patient follow-up.
Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Serum and tissue samples are collected for markers of inflammation and gene chip analysis
Non-Probability Sample
Subjects diagnosed with atherosclerosis
Atherosclerosis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
July 2013
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age range >17 years of age
  • Surgical carotid artery disease
  • Provide written informed consent and Authorization for Use/Disclosure of PHI

Exclusion Criteria:

  • History of carotid trauma
  • History of middle or large vessel vasculitis
  • Refusal to provide written informed consent and Authorization for
  • Use/Disclosure of PHI
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00861653
P06-31
No
Not Provided
Not Provided
Sarah Rinehart, MD
Piedmont Healthcare
Not Provided
Principal Investigator: Sarah Rinehart, MD Piedmont Healthcare
Piedmont Healthcare
April 2014